Deutsch E, Meziani L
Département de radiothérapie, Gustave-Roussy cancer campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Radiothérapie moléculaire et innovation thérapeutique, Gustave-Roussy cancer campus, université Paris-Saclay, Inserm U1030, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Radiothérapie moléculaire et innovation thérapeutique, Gustave-Roussy cancer campus, université Paris-Saclay, Inserm U1030, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Cancer Radiother. 2023 Sep;27(6-7):491-493. doi: 10.1016/j.canrad.2023.06.026. Epub 2023 Aug 16.
Radiation-induced pulmonary fibrosis (RIPF) is one of the major and late complications of radiotherapy (RT) with an average incidence rate between 16 and 28% after RT. RIPF significantly affects the function of the affected tissues/organs as well as the quality of life and survival of patients. The process of radiation fibrogenesis is initiated by a very complex signaling network that involves several cellular and molecular factors and the development of effective treatments relies on a better understanding of the involved mechanisms. Despite a major advance in the field, to date there is no clinical treatment that has really shown efficacy in the prevention or treatment of RIPF. In the present review, we will discuss potential new therapeutic avenues that could effectively treat RIPF.
放射性肺纤维化（RIPF）是放射治疗（RT）的主要晚期并发症之一，放疗后平均发病率在16%至28%之间。RIPF显著影响受影响组织/器官的功能以及患者的生活质量和生存率。辐射纤维化形成过程由一个非常复杂的信号网络启动，该网络涉及多个细胞和分子因素，有效治疗方法的开发依赖于对相关机制的更好理解。尽管该领域取得了重大进展，但迄今为止，尚无临床治疗方法真正显示出对RIPF的预防或治疗有效。在本综述中，我们将讨论可能有效治疗RIPF的潜在新治疗途径。
